Quotables
"If you build a better mousetrap, you will catch better mice."
George Gobel
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7429483 | Use of nerve growth factor for the storage, culture or treatment of cornea The nerve growth factor (NGF) is used for the storage of corneas in culture, for the production and the storage in vitro of single cell populations of the corneal morphological and functional unit (i.e. epithelium, stroma/keratocytes and endothelium) and of the conj... | 09/30/2008 |
| 7259180 | Methods and compositions for treatment of macular and retinal disease The present invention describes linking a therapeutic agent to a compound which is known to be naturally concentrated in a tissue affected by, or that is causing, a disease, to create a prodrug for treatment of the disease. Embodiments of the present invention inclu... | 08/21/2007 |
| 7186417 | Treatment of optic and otic inflammation There is provided a method of treating irritations and inflammation of the eye or ear by the topical administration of an aqueous composition containing an inorganic monobasic iodide salt and an oxidizing agent which is buffered to a pH of 4.0 to 8.0. The eye treati... | 03/06/2007 |
| 7109187 | Estrogenic compounds as anti-mitotic agents The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosa... | 09/19/2006 |
| 7087249 | Treatment of mucosal membranes The invention relates to the use of one or more antimicrobial metals preferably selected from silver, gold, platinum, and palladium but most preferably silver, formed with atomic disorder, and preferably in a nanocrystalline form, for reducing inflammation or infect... | 08/08/2006 |
| 7001607 | Artificial tear replacement solution A tear replacement solution that contains at least one water-soluble fluorosurfactant, water and a non-polar component, preferably in gel form, and a method for the external treatment for the eye of an mammal by applying the tear replacement solution to the eye, pre... | 02/21/2006 |
| 6969706 | Preserved pharmaceutical compositions comprising cyclodextrins A composition comprising a cyclodextrin, a guanidine-based cationic compound, and sorbic acid is disclosed herein. Preservatives and methods related thereto, and experimental results suggesting certain advantages related to these compositions, preservatives, and met... | 11/29/2005 |
| 6750196 | Methods of treating disorders of the eye In general, the present invention provides methods for promoting the function of retinal cells using neuregulins. A novel aspect of the invention involves the use of neuregulins as growth factors tp promote survival of retinal cells. Treating of the retinal cells to... | 06/15/2004 |
| 6716436 | Cosmetic composition for slimming containing L-arginine, an L-arginine analogue, or one of their derivatives, for topical application A cosmetic composition for slimming which includes, in combination with a cosmetically acceptable excipient, at least one compound having the formula (I) where R1 is a group bound by a peptidic bond and... | 04/06/2004 |
| 6703049 | Angiogenesis inhibitor The present invention relates to a novel angiogenesis inhibitor, more particularly, arsenolite (solid As4 O6) and composition containing the same. The arsenolite of the present invention inhibits endothelial cell proliferation and tu... | 03/09/2004 |
| 6683070 | Aqueous suspension with good redispersibility The aqueous suspension can be prepared by incorporating, in an aqueous suspension of a hardly soluble drug, a water-soluble polymer within the concentration range from the concentration at which the surface tension of the aqueous suspension of the drug be... | 01/27/2004 |
| 6605295 | Storage-stable ophthalmic compositions comprising diclofenac and ofloxacin The invention relates to stable ophthalmic preparations including the penetrant antiphlogistic diclofenac or salts thereof and the penetrant antibiotic ofloxacin present in the form of the racemate, an enantiomer, particularly levofloxacin, or the corresp... | 08/12/2003 |
| 6592907 | Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide An anti-microbial liquid ophthalmic composition for direct application onto an eye of a living being. The composition includes from about 0.02 wt. % to about 0.20 wt. % chlorite compound and from about 0.005 wt. % to about 0.01 wt. % peroxy compound, at a... | 07/15/2003 |
| 6565894 | Healthcare formulations comprising imidazole and hydrogen peroxide An ophthalmic solution comprising: 0.01 to 5 weight percent imidazole: 0.01 to 30 weight percent hydrogen peroxide and the balance water which can further comprisie 0.01 to 2 weight percent of a buffer adjusted so the pH of the formulation is between 5.5 ... | 05/20/2003 |
| 6537808 | Use of nerve growth factor for the storage, culture or treatment of cornea The nerve growth factor (NGF) is used for the storage of corneas in culture, for the production and the storage in vitro of single cell populations of the corneal morphological and functional unit (i.e., epithelium, stroma/keratocytes and endothelium) and... | 03/25/2003 |
| 6458854 | Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use Phospholipid-HETE derivatives, compositions and methods of use are disclosed. The compounds are particularly useful for treating dry eye.... | 10/01/2002 |
| 6458376 | Nonaqueous fluorinated drug delivery suspensions Nonaqueous pharmaceutical compositions for use in aqueous physiological systems are disclosed comprising drug delivery suspension of nonaqueous perfluorocarbon or fluorinated silicone liquid carriers. The suspended drug may be water labile or water stable... | 10/01/2002 |
| 6458853 | Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use Phospholipid-HETE derivatives, compositions and methods of use are disclosed. The compounds are particularly useful for treating dry eye.... | 10/01/2002 |
| 6448296 | Aqueous suspension with good redispersibility The aqueous suspension can be prepared by incorporating, in an aqueous suspension of a hardly soluble drug, a water-soluble polymer within the concentration range from the concentration at which the surface tension of the aqueous suspension of the drug be... | 09/10/2002 |
| 6432439 | O/W emulsion composition An O/W emulsion composition comprising fluorometholone or clobetasone butyrate, a phospholipid, an oil, a nonionic water-soluble cellulose derivative, and water. The O/W composition has advantages that fluorometholone or clobetasone butyrate contained the... | 08/13/2002 |
| 6423321 | Cytokine antagonists for the treatment of sensorineural hearing loss Specific Cytokine Antagonists, including TNF antagonists and/or Interleukin-1 antagonists, are used as novel therapeutic agents for the treatment of hearing loss, including presbycusis and other forms of sensorineural hearing loss. The present invention p... | 07/23/2002 |
| 6419944 | Cytokine antagonists for the treatment of localized disorders Cytokine antagonists for use in localized clinical disorders are provided for the treatment and prevention of damage to the optic nerve, other cranial nerves, spinal cord, nerve roots, peripheral nerves or muscles caused by any one of the following: a her... | 07/16/2002 |
| 6395309 | Use of an extract of Alchemilla vulgaris to inhibit angiogenesis Use of an extract of alchemilla vulgaris, or a fraction or a lyophilizate thereof, or one or more active principles contained in said extract, for inhibiting angiogenesis.... | 05/28/2002 |
| 6372785 | Synthesis of 1,8-dichloro-anthracene analogues and pharmaceutical compositions based thereon The invention provides novel anthracene compounds useful in the treatment of allergic, inflammatory, and tumor conditions and therapeutic compositions containing such compounds or their pharmaceutically acceptable salts. The compounds of the invention are... | 04/16/2002 |
| 6353032 | Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use Phospholipid-HETE derivatives, compositions and methods of use are disclosed. The compounds are particularly useful for treating dry eye.... | 03/05/2002 |
| 6331523 | Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5 The present invention relates to the use of FGF-5 polypeptides to delay, prevent or rescue retinal neurons, including photoreceptors, other retinal cells or supportive cells (e.g. Muller cells or RPE cells) from injury and degradation. Conditions comprehe... | 12/18/2001 |
| 6316465 | Ophthalmic uses of PPARgamma agonists and PPARgamma antagonists Methods of treating diseases of ocular tissues expressing the nuclear receptor PPARĪ³, by inhibiting the inflammatory response, the neovascularization and angiogenesis, and programmed cell death (apoptosis) in these target tissues, comprising administerin... | 11/13/2001 |
| 6277829 | Process for preparing of aqueous formulation for opthalmic use The present invention describes a process for the preparation of aqueous formulations containing azithromycin for ophthalmic use, as well any formulations obtained by this process and their topical use in the ocular bacterial infections, more preferably i... | 08/21/2001 |
| 6254893 | Composition for treating dry eye A calcium-based ophthalmic composition for treating dry eye including a hydrophobic carrier, such as petrolatum, and a calcium salt. Also a method for treating dry eye comprising the step of administering the composition according to the present invention... | 07/03/2001 |
| 6159458 | Sustained release ophthalmic compositions containing water soluble medicaments An ophthalmic composition that provides sustained release of a water soluble medicament is formed comprising a crosslinked carboxy-containing polymer, a medicament, a sugar and water. The composition has a pH of at least 6.7 but a viscosity of from about ... | 12/12/2000 |
| 6136334 | Medical uses of in situ formed gels Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical body cavity or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of... | 10/24/2000 |
| 6096733 | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application A topical drug application for the alleviation of kerato-conjunctivitis sicca (dry eye syndrome) is comprised of a solution of 17-ଲ-estradiol suspended or dissolved in a vehicle, and the method of preparation and application of the same. In the pref... | 08/01/2000 |
| 6080782 | Cyclohexyl dihydrobenzofuranes Compounds of formula I are selective cyclic nucleotide phosphodiesterase (PDE) inhibitors (namely of type IV). They and pharmaceutical compositions in which they are active ingredients are useful as bronchial therapeutics, for elimination of erectile dysf... | 06/27/2000 |
| 6060449 | Neovascularization inhibitor containing tissue factor pathway inhibitor There is provided an inhibitor of angiogenesis induced by growth of the vascular endothelial cells that comprises Tissue Factor Pathway Inhibitor (TFPI) as an active ingredient. The TFPI-containing preparation of the present invention can effectively inhi... | 05/09/2000 |
| 6051244 | Fructose diphosphate topical compositions Topical application of fructose-1,6-diphosphate, its derivatives and/or precursors are used for treating or preventing epidermal or mucosal aging and inflammation. In preferred embodiments, the fructose diphosphate (or its derivative) is applied in admixt... | 04/18/2000 |
| 5998390 | Combination of bisphosphonate and tetracycline Tissue-destructive conditions related to excess proteinase activity in a biological system are treated or prevented by administering to the system a composition which combines a tetracycline and a bisphosphonate in synergistic proteinase inhibiting amount... | 12/07/1999 |
| 5980928 | Implant for preventing conjunctivitis in cattle A method to reduce the likelihood of conjunctivitis in farm animals, especially cattle, includes the step of injecting an implant containing an antibiotic effective against the microbes associated with conjunctivitis subcutaneously into the animal in clos... | 11/09/1999 |
| 5958443 | Medical uses of in situ formed gels Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical body cavity or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of... | 09/28/1999 |
| 5922319 | Methods of treating eye conditions with human leukocyte elastase (HLE) inhibitory agents A method of reducing corneal scarring or fibroblast proliferation comprises applying to an area of a subject's eye afflicted with the condition a corneal scar-fibroblast proliferation-reducing amount of a free or polymer-bound HLE inhibitory agent under c... | 07/13/1999 |
| 5889030 | Method for stabilizing pranoprofen and stable liquid preparation of pranaprofen A method for stabilizing pranoprofen, comprising placing an aqueous solution of pranoprofen in coexistence with an antioxidant, or placing an aqueous solution of pranoprofen under the conditions of limited supply of oxygen, and a stable aqueous preparatio... | 03/30/1999 |
